A mitochondrial citrate transporter inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CTPI-2

Item No. 36933

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[[(4-chloro-3-nitrophenyl)sulfonyl]amino]-benzoic acid
CAS Number
68003-38-3
Molecular Formula
C13H9ClN2O6S
Formula Weight
356.7
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 2 mg/mlDMSO: 5 mg/ml
SMILES
O=C(C1=C(NS(=O)(C2=CC=C(C([N+]([O-])=O)=C2)Cl)=O)C=CC=C1)O
InChi Code
InChI=1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
InChi Key
NJTHPOSQGFJTDP-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 mg

    $44

    Add

    100 mg

    $84

    Add

    250 mg

    $132

    Add

    500 mg

    $242

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    CTPI-2 is an inhibitor of the mitochondrial citrate transporter, also known as SLC25A1.1 It decreases the oxygen consumption rate (OCR) in tumor spheres isolated from patients with non-small cell lung cancer (NSCLC) and inhibits the invasion of lung cancer stem cells in vitro. CTPI-2 (50 µM) acts synergistically with cisplatin (Item No. 13119) to reduce the viability of cisplatin-resistant patient-derived NSCLC cells. It reverses increases in body weight, steatosis, and fasting blood glucose levels in a mouse model of high fat diet-induced non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fernandez, H.R., Gadre, S.M., Tan, M., et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 25(7), 1239-1258 (2018).

    2. Tan, M., Mosaoa, R., Graham, G.T., et al. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 27(7), 2143-2157 (2020).